MassDevice Article: Device-agnostic Data Collection and The Future of Digital Health
MassDevice editor, Sean Whooley, recently wrote an article about how PhysIQ’s partnership with J&J’s Janssen Pharmaceuticals will advance digital therapeutics in a story published May 12, 2021: How PhysIQ is advancing digital therapeutics through its partnership with Janssen.
Product Creation Studio CTO, Scott Thielman, weighed in on the implications of this partnership to the future digital health landscape.
Article excerpt:
Over the course of the last year and some change, the impact of digital health and the need for it has increased by an immeasurable amount.
Virtual care became the norm after the COVID-19 pandemic hit, and, although a return to something resembling “normal” could be on the horizon, those at artificial intelligence–based technology developer PhysIQ see that the landscape has been reshaped since early 2020.
“Digital medicine has been evolving but a lot of what’s been done has been done in an exploratory capacity,” PhysIQ CCO Chris Economos told MassDevice. “COVID-19 has definitely changed that.”
In the throes of the pandemic in September, PhysIQ was among a number of companies to receive government contracts to aid in the battle against COVID-19.